This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbmt.2018.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.
Stem Cell Res Ther
December 2024
Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107, West Yan Jiang Road, Guangzhou, 510120, Guangdong, China.
Background: Allo-HSCT is a curative therapy for patients with transfusion-dependent thalassemia (TDT). The high incidence of transplant-related complications is becoming an obstacle to safe and effective unrelated donor (URD) transplantation.
Methods: In this retrospective study, we reported the survival outcomes and complications of transplantation in thalassemia patients using a novel regimen consisting of pre-transplantation immunosuppression (PTIS) and modified myeloablative conditioning based on intravenous busulfan, cyclophosphamide, fludarabine, and rabbit anti-human thymocyte immunoglobulin.
Antifragile Treatment for Efficient Chimerism of Induced Pluripotent Stem Cells Derived Hematopoietic Stem Cells.
Stem Cell Rev Rep
December 2024
Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, 08826, South Korea.
Article Synopsis
- Engraftable hematopoietic stem cells (HSC) can be sourced from bone marrow, umbilical cord blood, and peripheral blood, but finding a matched unrelated donor presents a challenge.
- The study focused on enhancing the efficiency of producing patient-specific induced pluripotent stem cell-derived hematopoietic stem cells (iHSC) by using an antioxidant treatment (ginsenoside Rg1) and verifying engraftment in mice models.
- Results showed that iHSC treated with Rg1 had high colony forming efficiency in vitro and successful engraftment in mice conditioned with high doses of busulfan, suggesting a new method for creating HSC that could be used in future transplants and potentially paired with gene-edit
Lentiviral Vector-Mediated Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model.
Hum Gene Ther
November 2024
Skeletal Dysplasia Research Lab, Nemours Children's Health, Wilmington, Delaware, USA.
Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disease caused by a mutation in the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) gene resulting in progressive systemic skeletal dysplasia. There is currently no effective treatment available for this skeletal condition. Thus, the development of a new therapy stands as an unmet challenge in reversing or alleviating the progression of the disease.
View Article and Find Full Text PDFSuperior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT.
Transplant Cell Ther
January 2025
Department of Hematology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Article Synopsis
- The study investigates the effectiveness of the fludarabine/intravenous busulfan (FB4) regimen in patients with myelodysplastic syndrome (MDS) undergoing stem cell transplantation from unrelated donors, comparing FB4 alone, FB4 with anti-thymoglobulin (ATG), and FB4 with low-dose total body irradiation (TBI).
- Results show that the combination of FB4 with low-dose ATG significantly improved overall survival (OS) and reduced nonrelapse mortality (NRM) compared to FB4 alone, whereas the FB4 with TBI did not demonstrate notable advantages over the FB4 regimen.
- The study highlights that using FB4 plus low-dose ATG is associated with better outcomes
Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
Br J Haematol
November 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Article Synopsis
- A phase II trial was conducted to test the efficacy of a high-dose decitabine treatment (MegaDAC) for patients with relapsed/refractory acute myeloid leukemia (R/R AML) who did not respond to other targeted therapies, enrolling 70 patients from 2019 to 2023.
- Despite previous treatments, all patients who underwent MegaDAC after allogeneic hematopoietic cell transplantation (allo-HCT) achieved minimal residual disease (MRD) negativity, showing a significant reduction in genetic abnormalities without major toxicity.
- The results indicate promising long-term outcomes for patients, with a 2-year cumulative incidence of relapse of 29.6% and overall survival rate of 58.6%, suggesting
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!